By end of March, Pfizer and Moderna expect to have delivered a total of 220 million vaccine doses to the U.S. government<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Feb. 24, 2021 (HealthDay News) — Officials from both Pfizer and Moderna delivered reassuring news about their COVID-19 vaccines to Congress on Tuesday: There will be a sharp rise in the delivery of doses in the coming month, and they will be able to provide enough doses to vaccinate most Americans by summer.<\/p>\n
By the end of March, Pfizer and Moderna expect to have delivered a total of 220 million vaccine doses to the U.S. government, a significant uptick from the roughly 82 million doses that the U.S. Centers for Disease Control and Prevention says have shipped so far.<\/p>\n
That encouraging news comes as federal regulators plan to weigh the emergency use of a third COVID-19 vaccine, from Johnson & Johnson, later this week. The Biden administration said Tuesday that it expects about 2 million doses of that vaccine to be shipped in the first week after approval, and the company told lawmakers it should provide enough of the single-dose option for 20 million people by the end of March, the Associated Press<\/em> reported.<\/p>\n By summer, Pfizer and Moderna said they expect to complete delivery of 300 million doses each, while J&J aims to provide an additional 100 million doses. That would be more than enough to vaccinate every American adult, the AP<\/em> reported. Two other manufacturers, Novavax and AstraZeneca, have vaccines in the pipeline and anticipate eventually adding to those totals.<\/p>\n The U.S. vaccination campaign continues to accelerate after a sluggish start and recent disruptions caused by a series of brutal winter storms. But state health officials say demand for shots still outstrips the weekly shipments they are given by the federal government.<\/p>\n